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Abstract
The priming of immune T cells by their interaction with dendritic cells (DCs) in lymph nodes (LN), one of the early events in
productive adaptive immune responses, occurs on a scaffold of lymphoid stromal cells, which have largely been seen as
support cells or sources of chemokines and homeostatic growth factors. Here we show that murine fibroblastic reticular
cells (FRCs), isolated from LN of B6 mice, play a more direct role in the immune response by sensing and modulating T cell
activation through their upregulation of inducible nitric oxide synthase (iNOS) in response to early T cell IFNc production.
Stromal iNOS, which only functions in very close proximity, attenuates responses to inflammatory DC immunization but not
to other priming regimens and preferentially affects Th1 cells rather than Th2. The resultant nitric oxide production does not
affect T cell-DC coupling or initial calcium signaling, but restricts homotypic T cell clustering, cell cycle progression, and
proliferation. Stromal feedback inhibition thus provides basal attenuation of T cell responses, particularly those
characterized by strong local inflammatory cues.
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Introduction
Naı¨ve T cells are activated through surface presentation of
peptide-MHC fragments by tissue-draining dendritic cells (DC).
While the cell biology and dynamics of this isolated interaction
have been extensively scrutinized[1–5], the interaction typically
takes place against the background of lymphoid stroma, a
collection of structural cells whose influence on the process has
not been fully investigated.
Four cell types constitute the majority of stroma in secondary
lymph nodes. Blood endothelial cells (BECs) are the structural cells
that are assembled to form capillaries and high-endothelial venules
(HEVs), structures T cells must traverse in order to enter the
lymph node. Lymphatic endothelial cells (LECs), assemble the
afferent and efferent lymphatic vessels, are largely contiguous with
lymphatics themselves, and provide entry sites for dendritic cells
arriving via lymph[6]. Within the lymph node, B cell zones are
isolated and supported by follicular dendritic cells (FDCs) whereas
fibroblastic reticular cells (FRCs) largely scaffold the T cell zone.
FRCs are thus the dominant stromal cell present at the site of T
cell priming. These cells engulf reticular collagen fibers that weave
throughout the T cell zone. The hollow core of the ensuing FRC
network provides a conduit for soluble material to penetrate into
the lymph node[7,8]. FRCs also provide structure to the T cell
zone and are hypothesized to act as ‘tracks’ for T cells to survey
the contents of a node and on which chemokines may be
immobilized for the purpose of guiding T cells[9]. They are also
major sources of CCL19, CCL21 and IL-7, key factors guiding T
cell motility and survival in the lymph node[10]. Finally, FRC
appear to be direct targets of some viruses, resulting in viral
modulation of CCL21 expression and possibly modulation of
lymphoid homeostasis[11,12]. In these various settings, FRC are
seen largely to promote T cell survival and activation.
In this study, we investigated whether FRCs directly communi-
cate with T cells activating in their midst and whether they are
capable of providing specific feedback in the T cell priming process.
We find that inclusion of FRC lines or freshly purified cells to T-DC
priming cultures results in significant inhibition of activation. This
inhibition does not rely on the FRC directly presenting antigens.
FRC s are highly responsive to T cell-produced interferon gamma
(IFNc) and respond by upregulating their transcription of the nos2
gene, encoding the enzyme inducible nitric oxide synthase (iNOS).
The resulting nearby production of nitrite results in a block in T cell
cell-cycle progression. We find that that iNOS inhibition during
specific types of priming reactions in the lymph nodes plays a
significant role in restricting T cell activation to immunization with
inflammatory DC populations, consistent with a role in regulating
the response. FRCs, prior and apart from this crosstalk, have no
discernable effect on T cell priming at the level of signaling or
expression of early activation markers. In sum, this places FRCs as
regulators of T cell activation through direct communication with
IFNc producing T cells.
Results
Lymph node stromal cell populations inhibit naive T cell
activation
In order to study the function of lymphoid stromal cells during
T cell priming, we first established cell lines from the CD45
negative fraction of the LN, representing FRCs (‘‘FRC.5’’: gp38+,
CD312), LECs (‘‘LEC.6’’: gp38+CD31+) and BECs (‘‘BEC.7’’:
gp382 CD31+) (Fig 1a). These lines, once established, were
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passaged up to 10 times from each freeze and re-sorted between
major freezes. These lines displayed distinct morphological
features, consistent with their functions in situ; FRCs featuring
very extended lamellopodia on plastic or glass surfaces and both
LECs and BECs having elongated phenotypes with long extension
(Fig 1b) and a high propensity to form side-by-side ‘bundles’ of
cells in 2D cultures (not shown).
We subsequently tested the effects of each line, as a 5% cellular
proportion, when co-cultured with a standard stimulation culture
of naı¨ve CD8 T cells, using monoclonal T cells derived from
lymph nodes of OTI TCR transgenic mice mixed with in-vitro
generated bone-marrow derived dendritic cells (BMDCs). T cells
were labeled with CFSE to track cell division and, as shown in
Fig 1c, in the absence of their cognate antigen, SIINFEKL (SL8),
they did not divide, regardless of the presence of lymph node
stromal lines. When BMDCs were pulsed with SIINFEKL
peptide, T cells typically underwent multiple rounds of cell
division within 48 hours. However, addition of FRC, LEC or BEC
Figure 1. Inhibition of Initial T cell priming by Lymph node Stromal Populations. (a) Three cell lines were isolated representing FRC (FRC.5:
CD312/gp38+)), LEC (LEC.6: CD31+gp38+), and BEC (BEC.7: CD31+gp382). (b) Contrast images of each line showing differences in morphology
consistent with their in vivo function. (c) 105 CFSE-labeled OTI T cells were incubated in 96-well round-bottom wells in the presence of 104 BMDCs
either unpulsed (NS) or pulsed (+SL8) with the indicated concentrations of SL8 peptides. 56103 stromal cells were added where indicated. Cells were
analyzed by FACS after 48 hours. (d) CFSE proliferation assays were performed identically to (a) but included freshly purified gp38+CD312 FRC or an
equal number of unfractionated total (including T cells, B cells, etc.) from collagenase digestion of lymph nodes. (e) Proliferation assays were
performed identically to those in (c,d) but included mouse embryonic fibroblasts (MEF) or NIH-3T3 cells as 3rd party cell types. All experiments are
representative of at least 3 similar trials.
doi:10.1371/journal.pone.0026138.g001
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cell lines each resulted in nearly complete inhibition of the induced
proliferation.
As T cell activation by DCs typically occurs in the T cell zone of
lymph nodes, scaffolded by FRCs, we focused predominantly on
these stromal cells and lines for subsequent studies. We first
confirmed that freshly isolated gp38+CD312 CD452 FRCs were
similarly inhibitory by assaying them in our T+DC stimulation
cultures. In these assays, we compared FRC isolates to a similar
number of total lymph node cells and found the FRCs (Fig 1d)
again to be inhibitory for proliferation of CD8 T cells. To test for
the specificity of inhibition, we also compared the FRC.5 line to
mouse embryonic fibroblast lines (MEF) and fibroblasts (NIH-3T3)
and found that whereas the latter lines also were modestly
inhibitory for proliferation, the FRC.5 line consistently inhibited to
a greater extent (Fig 1e). Given that the FRCs are present
proximally in the LN during priming whereas BEC and LEC are
not, we focused on the mechanism underlying their inhibition of
the response.
Inhibition of T cell activation by FRCs depends upon
interferon gamma production during priming
We first sought to determine the magnitude of T cell inhibition
and if it involved interactions between FRCs and DCs or was a
direct effect upon T cells, regardless of DC presence. In Fig 2a,
we added FRC.5 cells at varying levels to CFSE-loaded T cells and
primed with a selection of stimuli. A 10% fraction of FRCs
provided nearly complete blockade of T cell proliferation in
response to BMDCs loaded with SL8, plate-bound anti-CD3 +/2
soluble anti-CD28, or PMA plus ionomycin. However, when a
smaller FRC concentration was used, there was little or no effect in
some conditions but partial inhibition in the presence of aCD3
and aCD28. This implied that FRCs were not simply globally
repressing responses but, rather, that they did so specifically in
response to cues derived from the strength or type of activation of
the T cells. We quantified this finding by a different criterion in
Fig 2b–c. Here, we scored for the percentage of cells in the
culture that were in or beyond the first division, and term this ‘‘%
blasts’’. By this criterion, which measures the degree to which cells
are allowed to begin cycling, a greater distinction in the threshold
of FRC-based inhibition emerged. We interpret from this that
FRCs can very effectively inhibit the first cell division in some
conditions (i.e. at 2.5% or more) such that very few cells progress
to becoming ‘blasts’. In contrast, at the lower fractions (i.e. 1%),
they inhibit this to a lesser extent but, for some priming conditions
(e.g. BMDC), can prevent the maximal extent of cell cycling.
We used this same metric, while varying the number of BMDCs
in the culture in order to test whether higher densities of DCs
could overcome inhibition (Fig 2d). This revealed that the
inhibition at the higher levels of FRCs could not be overcome with
greater numbers of DCs, strongly suggesting that the inhibitory
effect was not due to FRCs somehow confining DCs from T cells.
The exclusion of such a mechanism was also supported by the
ability of FRCs to inhibit T cell proliferation to the fully soluble
PMA and Ionomycin stimulus (Fig 2a and Fig 2c).
Since it has been shown that distinct priming conditions result in
differences in both the quantity and quality of cytokines produced
by blasting T cells[13,14], we sought to determine the effect of
blocking select cytokines or adding them back to T+DC assays
(Fig 2e). While we saw little effect of aIL4 or aIL-12 antibodies
(data not shown), we found that addition of aIFNc almost fully
restored proliferation of T cells cultured with DCs in the presence
of FRCs. Interleukin 2 nor aIL-2 had a significant effect on FRC-
mediated inhibition of CFSE dilution. This implied that, at a
strength of stimulation resulting in strong IFNc secretion, FRCs
were licensed to inhibit the T cell response. That FRC might be
responsive to IFNc was also supported by their robust expression
of the IFNc receptor 1 (Fig 2f)
When FRCs were separated from T cells and DCs by a semi-
permeable membrane, the inhibitory effect was lost (Fig 2g).
Addition of IFNc itself also could not restore the inhibition in the
transwell context, suggesting that a lack of IFNc diffusion across
the transwell didn’t explain this effect. Combined with Fig 2e, this
implied that, while IFNc was involved, the inhibitory mechanism
required cell-cell or very close proximity between T Cells, DC,
and the modulating FRC population.
Regulation of T cell priming by IFNc-promoted Stromal
iNOS
We therefore turned toward assessing mechanisms by which
FRCs might inhibit T cell responses. Recent reports have shown
that viral infection of FRCs results in their upregulation of PDL-1,
an inhibitory molecule for T cells[12]. We assessed levels of PDL-1
as well as the costimulatory ligands CD86 (Fig 3a) and CD80
(data not shown). Whereas CD80 and CD86 levels were low and
remained unchanged, PDL-1 levels were indeed upregulated in
FRCs treated with IFNc. However, blocking these pathways did
not appreciably alter the proliferation of T cells in our assays
(Fig 3b), suggesting another mechanism. Since IFNc appeared to
be necessary for inhibition, we next examined the transcription of
nos2 gene and protein expression and the production of nitric
oxide (NO) which had previously been shown to be IFNc-
inducible in a selection of non-hematopoietic cells[15,16] as well as
cells of hematopoietic origin[17,18]. The nos2 gene encodes the
enzyme inducible nitric oxide synthase (iNOS), which is
responsible for production of nitric oxide and can be specifically
inhibited by the drug 1400W. As shown in Fig 3c, addition of
IFNc directly to FRC lines in the absence of T cells or DCs results
in an approximate 10-fold increase in transcription of the nos2
gene, an effect that was not directly altered by blocking the
enzyme itself with 1400W. Using antibodies to iNOS protein, we
were able to detect significant signal by immunofluorescence in
FRC lines and these levels were both quantitatively higher and
more localized to the cytosol in the presence of T plus DC (Fig 3d,
arrowhead highlights T-DC couple). Flow cytometry con-
firmed an upregulation of total iNOS levels in response to T+DC
augmented, compared to control (DC alone), and that this
augmentation could be blocked with antibodies to IFNc (Fig 3e).
We next measured accumulation of nitrite, a relatively-stable
end-product of nitric oxide, in our cultures using a standard Griess
assay[19]. Here, we found that addition of exogenous IFNc to
FRC cultures failed to increase production of nitrite to detectable
levels (Fig 3f), an effect that may suggest that release or further
activation of the enzyme requires additional signals delivered with
T cell activation. However, nitrite was detected when T cells were
stimulated in those cultures using SL8-loaded BMDCs, and this
was considerably augmented by inclusion of FRC in a concentra-
tion-dependent manner. Nitrite could not be detected when
unstimulated FRCs were plated. Finally, the nitrite that was
detected when FRCs were mixed with T cells plus peptide-loaded
DCs was blocked by the iNOS-specific inhibitor 1400W.
To test the emerging hypothesis that iNOS production was
responsible for FRC inhibition of T cell responses, we mixed T cells
plus SL8-loaded DCs together with FRCs in the presence or
absence of iNOS inhibition. As shown in Fig 4a, we could
completely restore proliferation of OTI CD8+ T cells by blocking
iNOS function with 1400W. Similarly, we could restore prolifer-
ation using the drug L-NMMA, a broader-spectrumNOS inhibitor.
When quantified as % blasts, this drug completely released cells to
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Figure 2. Regulation of T cell activation by LN Stromal cells via an IFNcmediated and proximity-dependent mechanism. (a–d) CD8+
T cell proliferation under various stimuli. Cultures were incubated for 48 hours prior to analysis by flow cytometry. (a) CFSE dilution profiles of OTI T
cells cultured with FRC.5 cells as well as either SL8 peptide-pulsed BMDCs (BMDC+SL8), plate-bound anti-CD3 (CD3), plate-bound anti-CD3 and
soluble anti-CD28 (aCD3/aCD28), or soluble PMA and Ionomycin. (b–d) The percentage of blasting OTI cells are represented as the percentage of
cells progressing past the first, non-proliferative, CFSE peak (% of Blasts). Cells were activated with various concentrations of FRC.5 under the
following conditions: (b) activated with 104 peptide-loaded BMDCs (c) plate-bound anti-CD3, plate-bound anti-CD3 and soluble anti-CD28, or soluble
Regulation of T Cell Priming by Lymphoid Stroma
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proceed into cycle (Fig 4b–c) with only very modest inhibition of
complete cycling of cells as assessed by CFSE peaks.
As iNOS has clearly been described as being produced by a
variety of macrophages[17,18], we wished to formally exclude that
our BMDC were not in some way responsible for the production
and inhibition. This was previously supported by our demonstra-
tion that FRC inhibited responses to anti-CD3 plus anti-CD28 or
PMA/Ionomycin (Fig 1) and also the demonstration that 1400W
augmented responses in the presence of FRC, but had no effect on
basal proliferation in their absence (Fig 4b–c). Consistent with this,
PMA and ionomycin and (d) various concentrations of total peptide-loaded BMDCs. (e) CFSE-based proliferation assay identical to that in (a) but also
including soluble cytokines or cytokine-blocking antibodies that were added at the start of the assay as indicated in the legend. (f) Expression of the
IFNc receptor in FRC.5 or freshly ex vivo isolated FRC was analyzed by FACS and compared to reagent control. (g) Proliferation assay of SE-efluor670
labeled OTI cells. 66105 OTI cells and 66104 peptide-loaded BMDCs cultured in contact with 66104 FRC.5 cells (proximal) or separated from FRC.5
cells by a 0.4um transwell membrane (distal). All assays were repeated in a minimum of 2 and typically 4–6 independent trials and all conditions were
assayed in triplicate. Error bars represent SD.
doi:10.1371/journal.pone.0026138.g002
Figure 3. IFNc dependent Induction of NOS2/iNOS/Nitrate production in Lymphoid stromal cells. (a) Costimulatory marker expression
on the surface of FRC.5 cells following IFNc treatment. (b) CFSE dilution profiles of OTI T cells stimulated with peptide-loaded BMDCs in the presence
or absence of FRC.5 cells and blocking antibodies to CD80, CD86, or PDL-1. (c) Real-time PCR expression of nos2 mRNA in FRC.5 cells cultured with
either IFNc, an iNOS-specific enzyme inhibitor (1400W), or both. (d) Immunofluorescence staining of NOS2 protein in FRC.5 cells cultured with pre-
labeled SL8-pulsed BMDC or in the presence of pre-labeled SL8-pulsed BMDC plus pre-labeled T cells. Teal lines around FRC in FRC/DC condition
indicate the border of the FRC and white arrowhead indicates a T-DC couple. Scalebar 20 mm. (e) Intracellular flow cytometry for NOS2 protein
expression by FRC.5 cells cultured with SL8-pulsed BMDC with or without T cells and with or without IFNc blockade for 48 hours. (f) Extracellular
nitrite concentration measured by Griess assay in FRC.5 cultures either alone; with OTI T cells and peptide-loaded BMDCs; or OTI cells, peptide-loaded
BMDCs, and 1400W.
doi:10.1371/journal.pone.0026138.g003
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Figure 4. A proximal role for iNOS during T cell priming by Lymphoid Stroma. (a) Proliferation of OTI cells stimulated with peptide-loaded
BMDCs in the presence or absence of FRC.5 cells and either a broad NOS inhibitor (L-NMMA) or the iNOS inhibitor,1400W. (b–c) Proliferation assays
identical to that in (a) but measuring the effect of NOS inhibitors under various concentrations of FRC.5 cells. (b) % Blasts quantified, demonstrating
FRC inhibition is reversible with iNOS blockade across a range of FRC concentration. (d) Proliferation of OTI cells stimulated with peptide-loaded
iNOS-/- BMDCs with or without added FRC. All assays were repeated in a minimum of 2 trials, and typically 4–6 independent trials and all conditions
Regulation of T Cell Priming by Lymphoid Stroma
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the stimulation of T cells using BMDC from mice genetically
lacking the iNOS gene was nevertheless dramatically inhibited by
stromal lines (Fig 4d). We noted that T cell inhibition by LEC or
BEC stroma appears to operate via a similar iNOS/IFNc
dependent mechanism (data not shown).
Although it is currently not possible to generate a mouse in which
deletion of iNOS is restricted to stroma and bone-marrow chimeras
to approximate this fail to fully reconstitute the lymphoid
compartment for unknown reasons (data not shown), we nevertheless
sought to determine whether our findings were consistent with iNOS
acting to attenuate T cell responses in lymph nodes. This was
particularly important since previous reports had noted a require-
ment for iNOS in augmenting immune responses, likely as a result of
its potent anti-microbial activity[20–22]. We therefore turned to the
use of a germline nos2 (iNOS) knockout and immunized in ways that
should engage the pathway we had studied in vitro and, conversely,
in ways that might not engage this mechanism. We additionally
chose to use tetramer staining to examine the response derived from
endogenous repertoire rather than using a TCR-transgenic adoptive
transfer system that may bias the outcome due to abnormally high
numbers of antigen-responsive cells.
To recapitulate our in vitro studies in which BMDC prime IFNc
production and the ensuing iNOS production, we first immunized
control or iNOS2/2 mice in the flank using the same BMDCs
pulsed with SL8 peptide. In this regimen, BMDC were always
iNOS proficient and so any change due to the genetic background
of the host would be due host cells beyond the APC. As shown in
Fig 4e–g iNOS deficiency resulted in an overall trend towards an
increased percentage of tetramer+ cells among total CD8 T cells
and a statistically significant increase (1.8 fold) in the absolute
number of tetramer+ CD8+ T cells in the lymph node at day 3.
As a comparison, we repeated this type of experiment but
sought to direct antigens to a resident DC population in the
absence of additional overt inflammatory cues. For this, we
targeted the relatively non-inflammatory DEC-205+/CD8+ DC
subset as antigen presenting cells[23] using anti-DEC205-OVA
antibody-protein conjugates[24]. In contrast to what was observed
using inflammatory DCs as the priming antigen presenting cells,
iNOS deficiency consistently resulted in a mild decrease in T cell
expansion as assessed using tetramer staining (Fig 4h–j). Together
this suggests that iNOS production during intra- lymph node
priming in the first 3 days does represent a mechanism of
regulating T cell responses, as predicted by our in vitro
experiments. Interestingly, and subject to further study, it also
indicates that iNOS is differentially engaged and utilized,
depending on the type of challenge and we would propose that
this may depend upon the cell types that are stimulated to produce
it and the local responses to this. The engagement of this pathway
during the first days of lymph node priming will represent fruitful
future study to understand the likely multiplicity of its action.
FRC inhibition depends on T cell production of IFNc and
is Th1 specific
A key prediction of these results is that T cells that do not make
IFNc will not engage this regulatory mechanism. To formally test
this, we assessed FRC-mediated inhibition of OTI cells lacking the
interferon gamma gene (IFNc2/2). As shown in Fig 5a, OTI T
cells lacking expression of IFNc were completely refractory to
FRC-mediated inhibition, even when they were present at
fractions as high as 10% of T cells. Confirming that this was
truly due to the loss only of IFNc, addition of exogenous IFNc to
these cultures re-established inhibition of T cell cycling.
This observation raised the possibility that FRCs might
specifically block certain types of T cells that make IFNc while
sparing those that do not. A classic dichotomy exists in CD4 T cell
subsets in which effector T helper 1 (Th1) cells produce IFNc but
no IL-4, whereas T helper 2 (Th2) cells produce IL-4 but no IFNc.
We therefore tested the prediction that FRCs would specifically
block cycling of restimulated Th1 clones while having little or no
effect on Th2 cells. As shown in Fig 5b–c, we found this to be the
case: Th1 cells loaded with SE-efluor670 dye had a significantly
higher MFI, indicative of less dilution and hence fewer rounds of
cell division, when cultured with FRCs whereas Th2 cells showed
no difference in MFI. Since blasts are heterogeneous in size and
proliferate quickly from the start of this assay, we do not observe
cells expressing undiluted levels of this dye. For this reason we did
not quantify %Blasts for this assay. Figure 5c demonstrates that
Th2 cells are insensitive to FRCs across a broad range of
concentrations while Th1 cells proliferate less (higher SE-
efluor670 MFI) as FRCs are added in increasing concentrations.
FRCs block cell-cycle progression but do not block initial
TCR recognition
We next turned toward dissecting the dynamics of how iNOS
functions during the priming response. We first assessed the ability
of T cells to form stable conjugates with DCs over time and found
no significant difference between T cells activated with BMDCs in
the presence of upwards of 25% FRCs (Fig 6a). Similarly, analysis
of calcium signaling profiles failed to detect significant differences in
the kinetics of intracellular calcium rise over the first 12 minutes
post BMDC contact, despite the readily available co-engagement of
these cells (Fig 6b). When examining the dynamics of the priming
reaction, the first sign of inhibition by FRCs occurred at
approximately 24 hours when cultures were examined for homo-
typic T-T clusters, correlating with successful activation[25,26].
This timeframe has previously been shown to correspond to early
IFNc production in T cells[27]. OTI T cells cultured with
SIINFEKL-pulsed DCs in the absence of FRCs displayed robust
clusters averaging 1.26104 mm2 in size while average cluster size in
the presence of FRC was 0.16104 mm2 (Fig 6c–d). This was, in
part, mediated by the action of iNOS/NO production as homotypic
clustering was partially restored by blockade with 1400W to an
average size of 0.56104 mm2. The remaining inhibition may suggest
a second mechanism that alters homotypic adhesiveness although
this will be subject of future work.
Interestingly, when we assessed CD25 and CD69 expression,
markers of early T cell activation, we found only a small difference
in CD25 upregulation at 24h when FRCs were added and no
difference in CD69 upregulation at this time, regardless of how
many FRC were in the culture (Fig 6e–f). In comparison,
however, when cells were assessed at 36 hours for cell-cycle
progression and the expression of Ki67, a marker of cell cycling,
the profiles of T cells activated in the presence of FRC were
identical to those of naı¨ve T cells, showing very significant
were assayed in triplicate. Error bars represent SD. (e–j) C57/Bl6 or iNOS2/2 mice were immunized subcutaneously with either SL8 peptide-loaded
BMDCs (e–g) or anti-DEC205-OVA conjugates (h–j) as described in Methods. Inguinal lymph nodes were isolated 3 days post-immunization, stained
and analyzed by flow cytometry. (e,h) Relative recovery of total CD8+ cells in the inguinal lymph nodes of C57/Bl6 (n = 4) immunized mice relative to
immunized iNOS2/2 mice (n = 4). (f,i) The percentage of tetramer positive cells in the CD8+ compartment post-immunization. (g,j) The number of
tetramer positive cells in immunized C57/Bl6 and iNOS2/2 mice.
doi:10.1371/journal.pone.0026138.g004
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inhibition of these measures. This effect was titratable: between 1
and 2.5% FRCs, both progression to G2/M and the expression of
Ki67 were reduced (Fig 6g–i). From this we conclude that the
interactions occurring after initial T-DC interaction, but prior to
approximately 36 hours, lead to the predominant inhibition of T
cell proliferation. From our other evidence, this is consistent with
published reports that OTI T cells generate IFNc within the first
24 hours[27] and (our data) that T cell IFNc production leads to
FRC expression of iNOS in a similar timeframe. Consistent with
our previous data, inhibition of NO production reverses the block
in cell-cycle and overall expansion of the T cells (Fig 6h–i)
Discussion
A key finding of this study is that FRCs are inhibitory to T cell
responses. This inhibition of cell-cycle progression clearly
depends upon a number of features of the priming reactions.
First, FRCs sense early IFNc. Thus, T cells that do not produce
extensive cytokines of this class are less restricted. It is interesting,
therefore, to note that Th2 cells are completely uninhibited by
these effects. This may provide a basal bias towards non-
inflammatory Th2 signaling, as T cells making these cytokines
might be less likely to provoke inhibitory signaling from stromal
sources. Speculatively, it may be that greater selective pressure
exists to restrain local Th1-type responses given their ability to
directly damage surrounding cells. In contrast, while grossly
unrestrained Th2-responses are clearly detrimental, local con-
trolled responses are more commonly associated with damage
repair and tissue-beneficial roles. To this extent, the most
important role of this mechanism might be tissue self-preservation
in addition to T cell ‘tolerance’.
How inhibitory are FRCs in situ? In our in vitro experiments,
we observed inhibition with as few as 1% FRCs relative to T cells.
A conservative estimate is that FRCs are on the order of 50–100
times more sparse than T cells on a per-cell basis, and thus our
assays are likely in the physiological range of cell number. In vivo,
however, effects are almost certainly local. NO itself will not persist
in interstitial spaces, largely because it nitrosylates proteins locally
and is thereby consumed. Thus, under typical priming situations,
there is unlikely to be ‘inhibition at a distance’. Rather only those
T cells that remain in contact with iNOS producing cells will be
inhibited in this way. This prediction is borne out in our transwell
experiments (Fig 2g), which show that inhibition is essentially
undetectable when cells are across the barrier, although there are
detectable levels of NO in supernatants (Fig 3f). One prediction of
this finding is that T cell responses that lead to extensive local
‘stopping’ of motile T cells within regions of the lymph nodes
would be more susceptible to this cross-talk as compared to more
transient and dynamic priming reactions. As clear modulation of
this remains difficult, we are presently unable to directly test this
prediction but the concept may force a re-evaluation of whether it
will always be beneficial for T cells to stably reside at a single site in
the lymph node, particular when IFNc is elicited.
A related and important feature of this mechanism is that it is
likely to not only be spatial, due to the short-range action of NO,
but also to be temporal due to a specific window of IFNc
production and then a lag until FRCs respond by making iNOS.
Bousso et. al recently showed that activated CD8 T cells produce
IFNc within 24-hours[27], thus providing a mechanism for our
early IFNc-iNOS axis. However, more typically, this cytokine may
peak many hours or even days later. This delay may account for
inhibition at 3+ days in vivo. In our hands, the method of priming
even for immunization regiments altered the magnitude by which
lymph node iNOS production affects priming. To this extent,
FRCs may be induced to fully produce iNOS in some very late-
stage responses and, given our finding that blasts can be inhibited
and that inhibition of naı¨ve cells occurs via late blocks in cell-cycle
progression, T cells may also be similarly inhibited by stroma in
these responses.
While FRCs are inhibitory, they are not alone in this capacity.
As shown in Figure 1e, it is likely that many cell types, when
added to T+DC priming reactions, may be inhibitory. This may
be due to a selection of inhibitory factors or simply nutrient
deprivation. However, the addition of IFNc blocking antibodies in
the FRC culture shows that the mechanisms by which FRCs
attenuate T cell responses are not ‘non-specific’ but rely on direct
Figure 5. FRC-mediated inhibition of IFNc producing CD4+ and
CD8+ T cells but not Th2 cells. (a) Percentage of blasting IFNc2/
2OTI T cells cultured with peptide-loaded BMDCs and various
concentrations of FRC.5 cells with or without exogenous IFNc. (b)
Dilution profiles of SE-eFluor670-labeled Th1 or Th2 skewed OTII cells
when cultured with peptide-bearing BMDCs in the presence or absence
of FRC.5 cells. (c) Quantification of SE-eFluor670 MFI (from (b)) as an
index of proliferation (higher MFI represents reduced proliferation.) All
experiments are representative of 2 similar trials. All conditions were
assayed in triplicate.
doi:10.1371/journal.pone.0026138.g005
Regulation of T Cell Priming by Lymphoid Stroma
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e26138
Figure 6. Inhibition of T cell activation by LN stromal lines occurs largely at the level of cell-cycle progression. (a) Percentage of
coupled OTI T cells and peptide-loaded BMDCs in the presence of various concentrations of FRC.5 cells. Cultures were analyzed at the times indicated
post addition of OTIs. (b) Ratiometric measurement of cytosolic Ca2+ flux in FURA-2AM loaded OTI T cells, immediately after contact with peptide-
bearing BMDCs in the presence or absence of FRC.5 cells. (c) Analysis of OTI and BMDC cluster area in the presence or absence of FRC.5 cells and iNOS
inhibitor (1400W). (d) Images of T cell clusters under the conditions described in (c). Scale bar represents 100 um. (c,d) Cultures were incubated for
48 hours prior to imaging analysis. (e) Surface staining of OTI T cells for activation markers CD25 and CD69 after 24 hours when cultured with
peptide-loaded BMDCs in the presence or absence of FRC.5 cells. Stains are compared to non-activated, naı¨ve OTI T cells. (f) Percent of OTI cells with
upregulated CD25 and CD69 levels following culture with BMDCs and various concentrations of FRC.5 cells for 36 hours. (g) Propidium iodide (PI)
incorporation and Ki67 levels in OTI T cells at 36 hours under identical culture conditions as those in (e). (h–i) PI incorporation and Ki67 levels in OTI
cells with various concentrations of FRC.5 cells. All experiments are representative of a minimum of 3 similar trials.
doi:10.1371/journal.pone.0026138.g006
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sensing of the response. In that regard, too, iNOS responses like
the ones discussed here have been previously reported in
macrophages[17] as well as mesenchymal stem cells [15] and
many other tissue stroma cells (e.g. in an accompanying paper by
Luther et al.) A key distinction between our studies and those
formerly mentioned is that we are now demonstrating this
pathway to be actively engaged during specific types of T cell
priming directly in the lymph node and via the lymph node
structural cells, suggesting a more integral role, in the latter, in
guiding the activation dynamics of Type 1-immune responses.
Is iNOS production by stromal cells always inhibitory to T cell
function? Our data using direct targeting to DEC-205 antigen
presenting cells indicates it most certainly will not be for all types of
priming in the T cell compartment. And, from the global immune
response, there are many reasons an ongoing immune response
benefits from iNOS production. Most prominently, iNOS is
upregulated in neutrophils in response to bacteria[28], is critical
for resistance to Leishmania[20], and Listeria infection[21]. In this
context, iNOS may lead to increased antigen presentation and
improved overall outcome. However and notably, these mice have
previously been shown to exhibit enhanced Th1 responses, a result
which now may be partly or fully explained by the mechanism we
describe here. The role of iNOS in the immune response therefore
continues to evolve and may play positive and negative regulatory
roles when expressed in stromal cells.
Methods
Mice
Ovalbumin-specific TCR transgenic OTI, OTII, OTI GFP and
OTI IFNc 2/2 mice were bred in-house. iNOS2/2 mice[22]
were gifts from L. Liu (University of California San Francisco) or
purchased from the Jackson Laboratory (B6.129P2-Nos2tm1Lau/J).
C57/Bl6 mice were purchased from the Simonsen Laboratory. All
mice were maintained under specific pathogen-free conditions at
the University of California San Francisco Animal Barrier Facility.
Experimental procedures were approved by the Institutional
Animal Care and Use Committee of the University of California
San Francisco under protocol authorization number AN081824-
03B.
Antibodies, reagents, and flow cytometry
Flow Cytometry and Cell Sorting. aCD31(clone 390),
agp38(clone 8.1.1), aCD45(clone 30-F11), aCD25(clone PC61),
aCD69(clone H1.2F3) and aCD8(clone 53-6.7) were purchased
from BioLegend. aCD86(clone B7-2) and aCD279/PD1(clone
J43) were purchased from eBioscience. aKi67(clone B56),
aCD19(clone 1D3), aNOS2(anti-iNOS/NOS type II, polyclonal)
and aIFNcR alpha chain(clone GR20) were purchased from BD.
Tetramers specific for SIINFEKL peptide (SL8) bound to H-2Kb
were purchased from ProImmune. For flow cytometry, cells were
first blocked with aCD16/32 (clone 2.4G2) and then stained in
PBS + 10% FCS with the antibodies listed above. For Intracellular
staining of NOS2, cells were surface stained as described above
(FACS only) and subsequently fixed 4% paraformaldehyde and
then permeablized in PBS +10%FCS+0.5% Saponin: staining
with aNOS2-FITC was then performed in this same
permeabilization buffer at 4uC. Data was collected on either an
LSRFortessa or a FACScalibur (BD) and analyzed using Flowjo
(Treestar).
In vitro and in vivo T cell activation. aCD3(clone 2C11,
produced in-house), aCD28(clone PV-1, University of California
San Francisco Hybridoma Core Facility, UCSF-HCF), SL8
peptide (Anaspec),Ovalbumin peptide (323-339) (Genscript)
PMA and ionomycin (Sigma-Aldrich). aCD40 (ebioscience), and
IFNc (Peprotech.) aDEC205-OVA (DEC-OVA) conjugates were
produced in-house, using established protocols3.
In vitro blocking. Antibodies against IFNc(clone XMG1.2,
BioXCell), IL2(clone JES6-1A12, ebioscience) and PD1(clone
RMP1-14, Biolegend). Antibodies against CD80(16-10A1) and
CD86(GL-1) were purchased from UCSF-HCF.
Cytokine Stimulation and inhibitors. 1400W and L-NG-
monomethyl Arginine citrate (L-NMMA) were purchased from
Sigma-Aldrich. IFNc, IL4 and IL2 were purchased from
Peprotech. IL2 was also produced in-house from transfected
lines. The cellular dyes propidium iodide, CFSE, DDAO and
FURA-2 AM were purchased from Invitrogen. Proliferation dye
eFluor670 was purchased from eBioscience.
Cell isolation
OTI T cells were isolated from the lymph nodes and spleen of 6
to 8 week old OTI mice. Selection was carried out using a negative
CD8 isolation kit (STEMCELL Technologies Inc.). Cells were
cultured in RPMI supplemented with 1 mM L-glutamine,
penicillin, streptomycin, 561025 M bME, and 10% FCS (R10).
Th1 and Th2 cells were produced by isolating the spleen of OTII
TCR transgenic mice and culturing 26106 cells with the following
combination of reagents. Anti-CD28, anti-IL4, IL12, IL2 and
Ovalbumin peptide (323–339) were added to produce Th1 cells.
Anti-CD28, anti-IFNc, IL4, IL2 and Ovalbumin peptide (323–
339) were added to produce Th2 cells. Bone marrow-derived
dendritic cells (BMDCs) were generated by culturing bone marrow
cells for 7–10 days with GM-CSF in IMDM supplemented with
1 mM l-glutamine, penicillin, streptomycin, 561025 M bME, and
10% FCS. IL4 was added for the last 2 days of culture.
Generation of stromal cell lines
Peripheral lymph nodes from C57/Bl6 mice were isolated and
ground between two microscope slides. Lymph node tissue was
then digested for 20 minutes at 37uC in 2 ml of RPMI 1640
medium containing 2% FCS, collagenase IV (2 mg/ml; Sigma-
Aldrich) and DNAseI (40 ug/ml; Roche). The tissue was then
washed and resuspended in RPMI 1640 containing 2% FCS,
collagenase D (1 mg/ml; Roche) and DNAseI (40 ug/ml) for
further digestion. Throughout the digestion procedure fragments
were gently sheared by passing through a 21.5 gauge needle every
10 minutes. When no visible fragments remained the sample was
washed in RPMI 1640 medium containing 5 mM EDTA and
finally resuspended in PBS containing 10% FCS at a concentra-
tion of 26106/ml. The resulting cell suspension was incubated at
room temperature with 0.1 mg of 2.4G2 for 15 minutes. Without
washing aCD31, agp38, aCD45, and 1 mg DAPI were added to
cells and incubated for an additional 30 minutes. Cells were then
washed in sterile PBS + 10% FCS and sorted using a BD
Biosciences FACSAria II Cell Sorter. Stromal populations were
defined as FRC (FRC.5) CD31(2) gp38(+), LEC (LEC.6)
CD31(+)gp38(+), and BEC (BEC.7) CD31(+) gp38(2) and sorted
in sterile RPMI 1640 containing 50% FCS and subsequently
washed and plated in sterile R10 media.
RNA isolation and RT-PCR
RNA was extracted using the RNeasy Mini Kit from Qiagen.
First strand synthesis was completed using random hexamers and
reagents from the SuperScript III kit purchased from Invitrogen.
100 ng of cDNA was amplified using a SYBR Green PCR Master
kit (Applied Biosystems) on a CFX96 real-time thermal cycler (Bio-
Rad). Expression of nos2 transcript is quantified as the amount
relative to the expression of the housekeeping gene hypoxanthine
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guanine phosphoribosyl transferase (Hprt1). This measure is
calculated with the following formula: 2Ct(Hprt1)-Ct(nos2) where
Ct(Hprt1) and Ct(nos2) represent the cycle number where the
signal is amplified to a threshold value that is held constant
between experiments. nos2 transcript was amplified using the
following primer sequences: ctcactgggacagcacagaa and
gcttgtctctgggtcctctg (Integrated DNA Technologies).
Proliferation assay
FRC.5 cells were plated at the amounts indicated, where ‘% of
FRC’ refers to the percentage of FRC.5 cells relative to the total T
cells in culture, in wells of a 96 well culture-treated dish 6 to
8 hours prior to the addition of T cells. OTI-GFP, Th1, Th2 and
OTI-IFNc2/2 T cells were purified as described above and
labeled with either 2 mM CFSE or 4 mM eFluor670 proliferation
dyes. 16105 T cells were added to FRC.5 cultures. Where
indicated, T cells were activated with peptide-loaded BMDCs
(16104 per well), plate-bound aCD3 (2 mg/ml), plate-bound
aCD3 (2 mg/ml) and soluble aCD28 (2 mg/ml), or PMA (2 ng/
ml) and ionomycin (20 ng/ml). BMDCs were matured with 1 mg/
ml LPS 1 day before addition to cultures and pulsed with SL8
peptide (100 ng/ml) or Ovalbumin peptide 323–339 (250 ng/ml)
for 1 hour. aCD3 was plated 16 to 24 hours prior to the addition
of FRC.5 cells. Where indicated, T cell proliferation was
augmented with the addition of various drugs, cytokines and
antibodies at the start of the assay. Cultures were stained or fixed
at the times noted and analyzed by flow cytometry.
T-DC coupling assay
For in vitro T-DC coupling, BMDCs were matured with LPS
(1 mg/ml) 1 day before priming and pulsed with SL8 peptide
(100 ng/ml) for 1 hour. BMDCs and naı¨ve OTI cells were labeled
with 4 mM DDAO and 4 mM eFluor670, respectively. OTI cells
were mixed with BMDCs at a ratio of T-DC 2:1. FRC.5 cells were
added in the amounts indicated and the cell mixture was
immediately centrifuged for 1 min at 228xg and incubated at
37uC. Cell mixtures were fixed at 15 minute intervals with an
equal volume of warm 4% PFA in PBS. Cells were analyzed by
flow cytometry for quantification of the percentage of couple
formation, calculated as the number of T cells in the double-
positive quadrant (eFluor670+ DDAO+) versus the total number
of T cells (eFluor670+).
Microscopy
The following techniques were used to image calcium flux in
OTI T cells. Wells of a Lab-Tek II chambered coverglass system
(Nunc) were plated with 7.56104 FRC.5 cells or fibronectin (1 mg/
ml) 16 hours prior to the addition of BMDCs and OTI T cells.
BMDCs were treated with LPS (1 mg/ml) 24 hours prior to the
start of the assay and pulsed with SL8 peptide (100 ng/ml) for 1
hour. Naı¨ve OTI-GFP cells were selected as described above and
labeled with 4 mM FURA-2 AM for 45 minutes at 37uC. 7.56104
peptide-loaded BMDCs were added to wells containing FRC.5
cells or fibronectin coating 5 minutes before the addition of 26105
labeled naı¨ve OTI cells. Interactions between BMDCs and OTI
cells were visualized on a modified Zeiss Axiovert 200 M
microscope with a 10x objective (Carl Zeiss). The microscope
was fitted with dual excitation and emssion filter wheels, a
Coolsnap-HQ camera (Photometrics) and a heated, motorized
stage. Metamorph (Universal Imaging) was used as the imaging
and control software. Data from DIC images, FURA emissions at
340 nm and 380 nm and green fluorescence were collected at 15-
second intervals over a 20 to 30 minute period. Calcium flux was
assessed based on the ratio of FURA-2 AM emissions at 340 nm to
those at 380 nm, with increased ratios indicating calcium flux.
Microscopy of NOS2 levels in mixed cultures utilized NOS2-
FITC conjugates as described for FACS, utilizing cultures in
which DC and/or T cells were separately pre-labeled prior to the
initiation of cultures with FRC. Data was collected on a wide-field
Zeiss 200 M microscope and analyzed in Metamorph.
The following techniques were used to image T cell clusters.
16104 FRC.5 cells or fibronectin were plated as described above.
6 hours later, 16106 naı¨ve OTI-GFP cells and 16105 SL8 loaded
BMDCs were added in the presence or absence of 1400W. Prior to
imaging, chambers were spun down at 400xg for 1 minute. Images
were captured on a modified Nikon Eclipse TE2000-S (Nikon).
The microscope utilized a CSU10 confocal scanner unit
(Yokagawa) and a XR Mega S-30 camera (Stanford Photonics).
A custom build of Micromanager was used to control image
acquisition. Data from DIC images and green fluorescence were
collected. Cluster area measurements were conducted using the
FIJI software suite of ImageJ.
Measurement of NO production
Nitrite concentrations in culture supernatant were measured by
the Griess assay as described previously[19]. Briefly, the culture
supernatant was mixed sequentially with an equal volume of 1%
sulfanilamide and 0.02% N-(1-naphthyl)ethylenediamine (0.5 M
HCl) in a 96-well microplate. The absorbance at 540 nm was
measured using a microplate reader, and the nitrite concentrations
were derived from standard curves.
Assessment of cell cycle status
Propidium iodide (PI) and Ki67 stains were performed on the
proliferation assays described above. Cultures were spun down at
400xg, medium was aspirated and replaced with 70% ethanol for
PI labeling or PBS containing 5% FCS and 0.5% saponin (Sigma-
Aldrich) for Ki67 staining. Cultures were incubated for 1 hour in
70% ethanol prior to washing and subsequent PI staining (10 ug/
ml in PBS containing 5% FCS). Percentage of cells actively cycling
(in S, G2, or M phase) was calculated by taking the number of cells
past the initial G0/G1 labeled peak and dividing by all live cells.
Ki67 staining was performed immediately upon the addition of
saponin medium. Cells were washed with PBS containing 10%
FCS and analyzed by flow cytometry.
Quantification of endogenous OVA-specific CD8 cells
Where indicated, mice were immunized with either BMDCs
loaded with peptide or aDEC205-OVA conjugates. BMDCs were
loaded with SL8 peptide (100 ng/ml) for 60 to 120 minutes at
37uC. Mice were immunized with a subcutaneous injection of
7.56105 BMDCs per flank in the presence of 200 ng/ml LPS in
PBS. DEC205-OVA conjugates (3 mg) were administered subcu-
taneously in both flanks. At the times indicated, mice were
euthanized and peripheral lymph nodes were excised. Lymph
node cells were stained with R-PE conjugated MHC-I pentamer
specific for the OVA peptide SIINFEKL in PBS containing 2%
FCS. Subsequently, cells were stained for CD8 and CD19 and
analyzed by flow cytometry.
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